Aralez Pharmaceuticals’ (NASDAQ:ARLZ) share price fell 60% today, leaving the Street at odds over when it will hit a bottom. The reason?
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced that the United States District Court for the District of New Jersey upheld the validity of two patents …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) investors have a smile on their faces following the news that CEO Adrian Adams acquired an additional 500,000 shares …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced the commercial launch of BLEXTEN (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced that it has entered into a rebate agreement with CaremarkPCS Health (also known as CVS Caremark), which secures …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced new data for YOSPRALA™, a recently FDA-approved prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a …
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced financial results for the third quarter ended September 30, 2016. The Company also highlighted certain corporate and commercial updates.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.
In a research note published Tuesday, Chardan analyst Keay Nakae reiterated a Buy rating on shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) with a price target …